Out of stock
ব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন
Register
0 People recently viewed this
Lanib 4
Drug International Ltd.
Generic: Lenvatinib Mesylate
Safety Advices
বাংলা
English
CONSULT YOUR DOCTOR
It is not known whether it is safe to consume alcohol with Lanib 4. Please consult your doctor.
CONSULT YOUR DOCTOR
Lanib 4 may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
CONSULT YOUR DOCTOR
Lanib 4 is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
CONSULT YOUR DOCTOR
It is not known whether Lanib 4 alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.
CAUTION
Lanib 4 should be used with caution in patients with kidney disease. Dose adjustment of Lanib 4 may be needed. Please consult your doctor.
CAUTION
Lanib 4 should be used with caution in patients with liver disease. Dose adjustment of Lanib 4 may be needed. Please consult your doctor.
Medicine Overview of Lanib 4mg Capsule
Introduction
Lanib 4 is an oral receptor tyrosine kinase inhibitor used in the treatment of thyroid cancer. Lanib 4 can be taken with or without food, but try to have it at the same time every day to get the most benefits. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects....
... Show moreUses of Lanib 4
- Thyroid cancer
Side effects of Lanib 4
Common
- Bleeding
- Cough
- Decreased appetite
- Erythema (skin redness)
- Hoarseness of voice
- Itching
- Joint pain
- Mouth sore
- Muscle pain
- Nausea
- Peripheral edema
- Rash
- Skin peeling
- Stomach pain
- Tiredness
- Vomiting
- Weight loss
How to use Lanib 4
Take this medicine in the dose and duration as advised by your doctor. Do not chew, crush or break it. Lanib 4 may be taken with or without food, but it is better to take it at a fixed time.
How Lanib 4 works
Lanib 4 is a tyrosine kinase inhibitor. It works by blocking the oxygen and nutrient supply to cancer cells due to which they stop growing.
Quick Tips
- Lanib 4 is used for the treatment of thyroid cancer.
- Take it with or without food, preferably at the same time each day.
- Diarrhea may occur as a side effect. Drink plenty of fluids and inform your doctor if it doesn't stop or if you find blood in your stools.
- Use a reliable contraceptive method to prevent pregnancy while you are taking this medicine and for a month after you stop taking it.
- Monitor your blood pressure regularly while taking this medication. Inform your doctor if you notice symptoms of very high blood pressure such as severe headache, confusion, problems with your eyesight, nausea or vomiting.
- It may cause serious bleeding problem. Inform your doctor if you get headaches, stomach pain or if you notice blood in your urine or stools.
- Do not take this medicine if you are pregnant, planning to conceive or breastfeeding.
Brief Description
Indication
Patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated, thyroid cancer. In combination with everolimus for the treatment of patients with, advanced renal cell carcinoma, following 1 prior vascular endothelial growth factor-targeted therapy.
Administration
Swallow capsule whole May take with or without food Take at the same time each day
Adult Dose
Adult Differentiated thyroid cancer (DTC) 24 mg once daily. Renal cell carcinoma (RCC) 18 mg in combination w/ everolimus 5 mg once daily. Patient w/ severe hepatic impairment Initially 14 mg once daily for DTC. 10 mg once daily for RCC.
Renal Dose
Patient w/ severe renal impairment Initially 14 mg once daily for DTC. 10 mg once daily for RCC.
Contraindication
Hypersensitivity. Lactation.
Mode of Action
Receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4) Also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet-derived growth factor receptor alpha (PDGFR-alpha), KIT, and RET
Precaution
Monitor BP after 1 wk of treatment then every 2 wk for the 1st 2 month & monthly thereafter. Monitor urine protein regularly. Actively managed GI toxicity to reduce the risk of development of renal impairment/renal failure. Monitor for clinical symptoms or signs of cardiac decompensation. Posterior reversible encephalopathy syndrome/reversible posterior leucoencephalopathy syndrome. Monitor liver function tests before initiation of treatment, then every 2 wk for the 1st 2 month & monthly thereafter during treatment. Adjust initial dose in patients w/ severe renal or hepatic impairment. Serious tumour-related bleeds including fatal haemorrhagic events, GI perforation & fistula formation may occur....
... Show moreSide Effect
>10% Percentages are for all grades of adverse effects unless otherwise noted Hypertension (73%),Diarrhea (67%),Fatigue (67%),Arthralgia/myalgia (62%),Decreased appetite (54%),Weight decreased (51%),Nausea (47%),Hypertension, grades 3-4 (44%),Stomatitis (41%),Headache (38%),Vomiting (36%),Proteinuria (34%),Palmar-plantar erythrodysesthesia (32%),Abdominal pain (31%),Dysphonia (31%),Constipation (29%),Oral pain (25%),Cough (24%),Peripheral edema (21%),Rash (21%),Dysgeusia (18%),Dry mouth (17%),Dizziness (15%),Dyspepsia (13%),Alopecia (12%),Epistaxis (12%),Insomnia (12%),Urinary tract infection (11%) 1-10% Percentages are for all grades of adverse effects unless otherwise noted Dental infections (10%) Hypotension (9%) Diarrhea, grades 3-4 (9%) Dehydration (9%) Prolonged QT interval (9%) Hypocalcemia (9%) Decreased appetite, grades 3-4 (7%) Hyperkeratosis (7%) Hypokalemia (6%) AST increased (5%) ALT increased (4%) Lipase increased (4%) Creatinine...
... Show moreInteraction
Decreased exposure w/ oral CYP3A4/Pgp substrates [eg, astemizole, terfenadine, cisapride, pimozide, quinidine, bepridil or ergot alkaloids (ergotamine, dihydroergotamine)]. May reduce effectiveness of oral hormonal contraceptives.
ব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন
Register
